Clue Partners with Leading Wearables for Enhanced Women’s Health Insights

Clue, a prominent women-led period and cycle tracking platform, has expanded its integration with several leading wearable technology companies, including Withings, Ultrahuman, WHOOP, Huawei, Polar, Fitbit, Noise, and Luna. This initiative, announced on November 17, 2025, aims to provide users with deeper insights into their health, particularly regarding menstrual and hormonal patterns, by connecting wearable device data with Clue’s tracking capabilities.

The new partnerships build on Clue’s existing collaboration with ŌURA, which began in 2023. This expansion underscores Clue’s commitment to helping women and individuals with cycles gain a better understanding of their health. The integration of wearable technology reflects a growing trend, as over 60% of respondents in a recent Clue survey indicated they use or would consider using wearables to monitor their health, with nearly 40% expressing interest in tracking their menstrual cycle through these devices.

Enhanced Tracking Features

The new features will allow Clue users to monitor sleep duration and skin temperature alongside their menstrual cycle data. This multifaceted approach aims to provide clearer insights into how various health metrics interact during different phases of the menstrual cycle, such as ovulation and perimenopause.

Key steps in this process include:

1. **Continuous tracking**: Wearable devices will passively record data on skin temperature and sleep duration.

2. **Smart sync**: Data will be securely transferred to the Clue app, integrating with self-reported symptoms and cycle information.

3. **Contextual insights**: Users will be able to identify patterns related to their menstrual cycle, which can inform lifestyle choices and health goals.

Clue’s CEO, Rhiannon White, emphasized the importance of these advancements: “Our mission at Clue is to help women and people with cycles understand their bodies and take control of their health. Expanding our partner ecosystem enhances our members’ experience and contributes to our growth as a trusted platform for women’s health data globally.”

Exclusive Offers for Users

To facilitate these integrations, Clue and its partners are providing exclusive bundles and discounts to users. For instance, customers purchasing a Withings ScanWatch 2 will receive an annual subscription to Clue Plus, with prices set at $379.95 in the US, €359.90 in the EU, and £319.95 in the UK. Other partnerships include similar offers from Ultrahuman, WHOOP, Polar, Fitbit, and Luna, allowing users to access Clue Plus at discounted rates or with free trials.

This collaboration is not only about technology integration but also about empowering women in their health journeys. Alexi Coffey, Vice President of Product at WHOOP, remarked, “We’re proud to partner with Clue to help women better understand their health across every stage of life.” Similarly, Kate Davies, Vice President of Medical, Women’s Health & Longevity at Ultrahuman, highlighted the importance of offering women choices in health tracking.

Clue’s platform supports various modes, including Clue Period Tracking, Clue Conceive, Clue Pregnancy, Clue Perimenopause, and Clue Tracking without periods. All integrations are available exclusively to Clue Plus subscribers, enhancing the overall user experience.

Final Thoughts

As women increasingly seek personalized health tracking solutions, Clue’s expanded partnerships with leading wearables signify a significant step forward in providing comprehensive health insights. The integration of menstrual cycle data with wearable health metrics offers users a more nuanced understanding of their bodies, empowering them to make informed health decisions.

For further information on Clue and its services, visit their website at helloclue.com.

Please note that while Clue Plus and wearables integration are designed to enhance self-awareness, they do not replace professional medical advice. Users are encouraged to consult healthcare professionals with any medical concerns.